Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or...

Authors :: Li, Daneng
Rau, Kun-Ming
Yu, Ming-Lung
Chon, Hong Jae
Lai, Hsueh-Chou
Pelster, Meredith
Roberts, Stuart K.
Crysler, Oxana V.
Vaccaro, Gina M.
Womack, Mark Sanders
Kim, Ju Won
Yang, Jin-Mo
Kim, Hyung-Don
Hill, Jonathan
REICHERT, VIENNA Lynn
Masia, Ricard
Harshman, Lauren C
Hsu, Chih-Hung
Kang, Yoon-Koo
Source :: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p470-470, 151p
Publication Year :: 2024

Full Text Access

Tools